Karen L. Smith
CIK 1639637 · Chief Medical Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XLRN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
5TH FL, WATERLOO EXCHANGE, WATERLOO RD
DUBLIN L2 4, L2 0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNTX | Director | — | $0.24 | — | $0 | 3 | 2026-06-26 |
| SKYE | Director | — | $1.57 | — | $0 | 5 | 2026-04-02 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 102,100 | $0.18 | $18.1K | $0 | 9 | 2025-06-16 |
| AUPH | Director | 24,807 | $17.04 | $422.7K | -$44.2K | 3 | 2024-11-25 |
| Tourmaline Bio, Inc. (TALS) Delisted | Director | — | $27.20 | — | $0 | 3 | 2023-06-14 |
| QNCX | Chief Medical Officer | — | $31.73 | — | $0 | 1 | 2023-02-02 |
| Quince Therapeutics, Inc. (CRTX) Delisted | Chief Medical Officer | 194,690 | $1.95 | $379.6K | $0 | 2 | 2022-05-27 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 0 | $178.75 | $0 | -$2.88M | 8 | 2021-11-22 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| EBS | EVP, Chief Medical Officer | 11,888 | $6.34 | $75.4K | $0 | 2 | 2021-05-11 |
| JAZZ | EVP, R&D and CMO | 28,474 | $205.70 | $5.86M | $250.0K | 13 | 2018-03-07 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | — | — | — | $0 | 1 | 2018-02-13 |
Recent Filings · Page 3 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-17 | Tourmaline Bio, Inc. (TALS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-01 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
| 2021-11-22 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −1,622 | $0 | EDGAR |
| 2021-06-14 | ANTARES PHARMA, INC. (ATRS) Delisted | Grant (A) | +25,452 | $112.5K | EDGAR |
| 2021-05-11 | EBS | Tax (F) | −305 | -$18.6K | EDGAR |
| 2021-04-05 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −2,939 | -$1.30M | EDGAR |
| 2021-04-02 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$854.6K | EDGAR |
| 2021-03-01 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +8,200 | $0 | EDGAR |
| 2021-02-26 | EBS | Grant (A) | +5,883 | $0 | EDGAR |
| 2021-02-02 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +1,622 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.